The Role of MicroRNAs in the Pathogenesis and as Biomarkers for Pediatric Epilepsy: A Systematic Review.

IF 4.1 3区医学 Q1 GENETICS & HEREDITY

Molecular Diagnosis & Therapy Pub Date : 2025-06-08 DOI:10.1007/s40291-025-00791-9

Fady Zakaria, Steven Amged Yousef, Janna AbdelDayem, Rawan ElGamal, Omar Y Issa, Mohamed Mansour, Harvey Bastorous, Eslam Emad, Rudayna Mahgoub

{"title":"The Role of MicroRNAs in the Pathogenesis and as Biomarkers for Pediatric Epilepsy: A Systematic Review.","authors":"Fady Zakaria, Steven Amged Yousef, Janna AbdelDayem, Rawan ElGamal, Omar Y Issa, Mohamed Mansour, Harvey Bastorous, Eslam Emad, Rudayna Mahgoub","doi":"10.1007/s40291-025-00791-9","DOIUrl":null,"url":null,"abstract":"Purpose: Epilepsy is highly prevalent among children, making it one of the most common neurological diseases in the pediatric population. Its diagnosis is problematic, largely depending on clinical judgment and inaccurate investigative studies. Thus, a more objective investigation is warranted. MicroRNAs (miRNAs) are small molecules found in various body fluids and tissues that prove to have potential, as they play an important role in the pathogenesis of epilepsy. This review evaluates the use of miRNAs in the diagnosis, prediction, and prognosis of pediatric epilepsy. Furthermore, it discusses the use of miRNAs as therapeutic agents and the relationship between miRNAs and antiepileptic drugs (AEDs).Methods: From inception until 7 July 2024, a thorough search of PubMed, Europe PMC, PubMed Central, and Google Scholar was conducted.Results: Our review is based on 18 studies on pediatric patients with epilepsy according to the selection criteria. A total of 33 different miRNAs for diagnosis, 13 for prediction, and 2 for prognosis of pediatric epilepsy in a total sample size of 663, 111, and 163 pediatric patients, respectively, in addition to 20 miRNAs for the diagnosis of focal epilepsy, and a further 4 for generalized epilepsy in the same population were interpreted in our systematic review.Conclusions: These studies suggest that miRNA usage as a diagnostic, predictive, and prognostic biomarker for pediatric patients with epilepsy is promising. However, further research on that population is needed, as the number of studies is limited, with several bias concerns and heterogeneity, with the need for clinical trials to assess the use of miRNAs as drug agents. PROSPERO registration no. ID: PROSPERO 2024 CRD42024578258.","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Diagnosis & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40291-025-00791-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Epilepsy is highly prevalent among children, making it one of the most common neurological diseases in the pediatric population. Its diagnosis is problematic, largely depending on clinical judgment and inaccurate investigative studies. Thus, a more objective investigation is warranted. MicroRNAs (miRNAs) are small molecules found in various body fluids and tissues that prove to have potential, as they play an important role in the pathogenesis of epilepsy. This review evaluates the use of miRNAs in the diagnosis, prediction, and prognosis of pediatric epilepsy. Furthermore, it discusses the use of miRNAs as therapeutic agents and the relationship between miRNAs and antiepileptic drugs (AEDs).

Methods: From inception until 7 July 2024, a thorough search of PubMed, Europe PMC, PubMed Central, and Google Scholar was conducted.

Results: Our review is based on 18 studies on pediatric patients with epilepsy according to the selection criteria. A total of 33 different miRNAs for diagnosis, 13 for prediction, and 2 for prognosis of pediatric epilepsy in a total sample size of 663, 111, and 163 pediatric patients, respectively, in addition to 20 miRNAs for the diagnosis of focal epilepsy, and a further 4 for generalized epilepsy in the same population were interpreted in our systematic review.

Conclusions: These studies suggest that miRNA usage as a diagnostic, predictive, and prognostic biomarker for pediatric patients with epilepsy is promising. However, further research on that population is needed, as the number of studies is limited, with several bias concerns and heterogeneity, with the need for clinical trials to assess the use of miRNAs as drug agents. PROSPERO registration no. ID: PROSPERO 2024 CRD42024578258.

查看原文本刊更多论文

microrna在儿童癫痫发病机制中的作用和作为生物标志物：系统综述。

目的：癫痫在儿童中非常普遍，使其成为儿科人群中最常见的神经系统疾病之一。它的诊断是有问题的，很大程度上取决于临床判断和不准确的调查研究。因此，有必要进行更客观的调查。MicroRNAs （miRNAs）是一种存在于各种体液和组织中的小分子，在癫痫的发病机制中发挥着重要作用。本综述评估了mirna在小儿癫痫的诊断、预测和预后中的应用。此外，本文还讨论了miRNAs作为治疗药物的用途以及miRNAs与抗癫痫药物（AEDs）之间的关系。方法：从成立到2024年7月7日，全面检索PubMed、Europe PMC、PubMed Central和谷歌Scholar。结果：我们的综述是基于18项儿童癫痫患者的研究，并按照选择标准进行的。在我们的系统综述中，共有33种不同的mirna用于儿童癫痫的诊断，13种用于预测，2种用于预后，分别在663,111和163例儿科患者的总样本量中，除了20种用于局灶性癫痫的mirna，还有4种用于全面性癫痫的mirna在同一人群中进行了解释。结论：这些研究表明，miRNA作为儿科癫痫患者的诊断、预测和预后生物标志物是有希望的。然而，由于研究数量有限，存在一些偏倚问题和异质性，需要对该人群进行进一步研究，并且需要进行临床试验来评估miRNAs作为药物的使用。普洛斯彼罗注册号：Id: prospero 2024 crd42024578258。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Diagnosis & Therapy 医学-药学

CiteScore

7.80

自引率

2.50%

发文量

审稿时长

>12 weeks

期刊介绍： Molecular Diagnosis & Therapy welcomes current opinion articles on emerging or contentious issues, comprehensive narrative reviews, systematic reviews (as outlined by the PRISMA statement), original research articles (including short communications) and letters to the editor. All manuscripts are subject to peer review by international experts.